» Articles » PMID: 35257600

Incorporating Estimands into Clinical Trial Statistical Analysis Plans

Overview
Journal Clin Trials
Publisher Sage Publications
Date 2022 Mar 8
PMID 35257600
Authors
Affiliations
Soon will be listed here.
Abstract

Background: International Council for Harmonisation (ICH) E9 was developed as a consensus guidance document to encourage worldwide harmonization of the principles of statistical methodology in clinical trials. Addendum E9 (R1) clarified and extended ICH E9 with a focus on estimands and sensitivity analyses. Since the release of E9 (R1), clinical trial protocols have included estimands, but there is variation in how they are presented. Statistical analysis plans (SAPs) are increasingly becoming publicly available (e.g. posting on ClinicalTrials.gov) and present an opportunity to link estimands with planned analyses to present the alignment of trial objectives, design, conduct, and analysis.

Methods: A table format was used to create a template for inclusion in SAPs that satisfies ICH E9 (R1) guidance to align statistical analysis to the estimand. The template provides a consistent structure for presentation of estimands and the associated analysis, and is applicable to a wide range of trial designs. We illustrate use of the template with a hypothetical clinical trial in HIV-1.

Results: The estimand-to-analysis table template starts with the study objective describing the clinical question of interest as written in the trial protocol. The remainder of the table describes each attribute of the estimand (treatment, target population, variable, intercurrent events, and population-level summary) in the left column (ESTIMAND), while the right column describes how each attribute will be handled using the data collected in the clinical trial (ANALYSIS). The template was applied to a hypothetical, early-phase single-arm trial, modeled after a pediatric trial in HIV, where the objective was to determine the safety of a new antiretroviral drug as part of a combination antiretroviral treatment regimen in the pediatric population. Three intercurrent events were illustrated in the table: death, premature treatment discontinuation before 24 weeks, and pregnancy. An estimand-to-analysis table from a grant application that addresses the primary objective of a placebo-controlled randomized trial is also presented to demonstrate an alternative usage.

Conclusion: We found the template to be useful in study design, providing a snapshot of the objective, target population, potential intercurrent events, analysis plan, and considerations for missing data in one place and facilitating discussion among stakeholders. The proposed standardized presentation of estimand attributes and analysis considerations in SAPs will provide guidance to SAP authors and consistency across studies to facilitate reviews.

Citing Articles

Statistical methods for clinical trials interrupted by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic: A review.

Basu J, Parsons N, Friede T, Stallard N Stat Methods Med Res. 2024; 33(11-12):2131-2143.

PMID: 39474813 PMC: 11577686. DOI: 10.1177/09622802241288350.


Current developments of the estimand concept.

Fierenz A, Zapf A Pharm Stat. 2024; 23(6):864-869.

PMID: 38676433 PMC: 11602887. DOI: 10.1002/pst.2395.


Making causal inferences from transactional data: A narrative review of opportunities and challenges when implementing the target trial framework.

Esteban S, Szmulewicz A J Int Med Res. 2024; 52(3):3000605241241920.

PMID: 38548473 PMC: 10981242. DOI: 10.1177/03000605241241920.


Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial.

Batmunkh T, Moore K, Thomson H, Altangerel B, Amraa O, Avaa N Lancet Reg Health West Pac. 2024; 42:100953.

PMID: 38357398 PMC: 10865044. DOI: 10.1016/j.lanwpc.2023.100953.


PROMISE: effect of protein supplementation on fat-free mass preservation after bariatric surgery, a randomized double-blind placebo-controlled trial.

Taselaar A, Boes A, de Bruin R, Kuijper T, Van Lancker K, van der Harst E Trials. 2023; 24(1):717.

PMID: 37946272 PMC: 10636856. DOI: 10.1186/s13063-023-07654-w.


References
1.
Meyer R, Ratitch B, Wolbers M, Marchenko O, Quan H, Li D . Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic. Stat Biopharm Res. 2021; 12(4):399-411. PMC: 8011486. DOI: 10.1080/19466315.2020.1779122. View

2.
Goff Jr D, Lloyd-Jones D, Bennett G, Coady S, DAgostino R, Gibbons R . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 129(25 Suppl 2):S49-73. DOI: 10.1161/01.cir.0000437741.48606.98. View

3.
Mehrotra D . A note on the draft International Council for Harmonisation guidance on estimands and sensitivity analysis. Clin Trials. 2019; 16(4):339-344. DOI: 10.1177/1740774519844259. View

4.
Wharton S, Astrup A, Endahl L, Lean M, Satylganova A, Skovgaard D . Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data. Int J Obes (Lond). 2021; 45(5):923-933. PMC: 8081661. DOI: 10.1038/s41366-020-00733-x. View

5.
Little R, DAgostino R, Cohen M, Dickersin K, Emerson S, Farrar J . The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012; 367(14):1355-60. PMC: 3771340. DOI: 10.1056/NEJMsr1203730. View